Crohn's Disease Therapeutics Market Size, Share & Trends Analysis Report By Type, By Route of Administration (Injectable, Oral), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024

Description

Crohn's Disease Therapeutics Market Growth & Trends:

The global crohn's disease therapeutics market size is expected to reach USD 16.28 billion in 2030 and is projected to grow at a CAGR of 2.7% from 2024 to 2030. Increasing awareness of the disease, coupled with rising initiatives by regulatory bodies for development of novel treatment options, is estimated to provide the market with high growth potential.

For instance, the American Gastroenterological Association (AGA), in collaboration with Pfizer, supports research projects related to inflammatory bowel diseases and has offered three grants in their name. The Crohn's & Colitis Foundation, European Federation of Crohn's & Ulcerative Colitis Associations, and American Autoimmune Related Diseases Association are some of the organizations providing funds for research.

Furthermore, increase in prevalence of Crohn's disease has directed many companies to collaborate with various regulatory bodies and research institutes to introduce novel and effective treatment for the condition. In 2016, Pfizer's Centers for Therapeutic Innovation (CTI) collaborated with Johns Hopkins University to discover new medicines to treat Crohn's disease and ulcerative colitis.

Crohn's Disease Therapeutics Market Report Highlights:

Non-surgical dominated the market and accounted for a share of 70.3% in 2023 owing to the advancements in medication and the development of powerful biological therapies and biosimilars that effectively manage Crohn's disease
North America crohn's disease therapeutics dominated the market in 60.25% of the global revenue in 2023. High incidences of Chron's in patients are one of the major growth drivers
Some of the key players in the market are Johnson & Johnson Services Inc.; Pfizer Inc.; Allergan; and AbbVie Inc.

Product Code: GVR-2-68038-424-6

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Crohn's Disease Therapeutics Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Crohn's Disease Therapeutics Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Crohn's Disease Therapeutics Market: Type Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Crohn's Disease Therapeutics Market: Type Movement Analysis, USD Million, 2023 & 2030
4.3. Non-Surgical
- 4.3.1. Non-Surgical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  - 4.3.1.1. Anti-inflammatory Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  - 4.3.1.2. Immune System Suppressors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  - 4.3.1.3. Antibiotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  - 4.3.1.4. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Surgical
- 4.4.1. Surgical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Crohn's Disease Therapeutics Market: Route of Administration Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Crohn's Disease Therapeutics Market: Route of Administration Movement Analysis, USD Million, 2023 & 2030
5.3. Injectable
- 5.3.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Oral
- 5.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Crohn's Disease Therapeutics Market: Distribution Channel Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Crohn's Disease Therapeutics Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
6.3. Hospital Pharmacies
- 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Retail Pharmacies
- 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Online Pharmacies
- 6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Crohn's Disease Therapeutics Market: Regional Estimates & Trend Analysis

7.1. Crohn's Disease Therapeutics Market Share, By Region, 2023 & 2030, USD Million
7.2. North America
- 7.2.1. North America Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
  - 7.2.2.1. U.S. Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.3. Canada
  - 7.2.3.1. Canada Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.4. Mexico
  - 7.2.4.1. Mexico Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
- 7.3.1. Europe Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. UK
  - 7.3.2.1. UK Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Germany
  - 7.3.3.1. Germany Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. France
  - 7.3.4.1. France Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.5. Italy
  - 7.3.5.1. Italy Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.6. Spain
  - 7.3.6.1. Spain Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.7. Denmark
  - 7.3.7.1. Denmark Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.8. Sweden
  - 7.3.8.1. Sweden Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.9. Norway
  - 7.3.9.1. Norway Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
- 7.4.1. Asia Pacific Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. China
  - 7.4.2.1. China Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Japan
  - 7.4.3.1. Japan Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. India
  - 7.4.4.1. India Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.5. South Korea
  - 7.4.5.1. South Korea Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.6. Australia
  - 7.4.6.1. Australia Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.7. Thailand
  - 7.4.7.1. Thailand Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
- 7.5.1. Latin America Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
  - 7.5.2.1. Brazil Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Argentina
  - 7.5.3.1. Argentina Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Saudi Arabia
  - 7.6.2.1. Saudi Arabia Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. UAE
  - 7.6.3.1. UAE Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. South Africa
  - 7.6.4.1. South Africa Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Kuwait
  - 7.6.5.1. Kuwait Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
- 8.4.1. Takeda Pharmaceutical Company Limited
  - 8.4.1.1. Participant's Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Recent Developments/Strategic Initiatives
- 8.4.2. AbbVie Inc.
  - 8.4.2.1. Participant's Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Recent Developments/Strategic Initiatives
- 8.4.3. Perrigo Company plc
  - 8.4.3.1. Participant's Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Recent Developments/Strategic Initiatives
- 8.4.4. Pfizer Inc.
  - 8.4.4.1. Participant's Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Recent Developments/Strategic Initiatives
- 8.4.5. Johnson & Johnson Services Inc.
  - 8.4.5.1. Participant's Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Recent Developments/Strategic Initiatives
- 8.4.6. Ferring B.V.
  - 8.4.6.1. Participant's Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Recent Developments/Strategic Initiatives
- 8.4.7. Bristol-Myers Squibb Company (Celgene Corporation)
  - 8.4.7.1. Participant's Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Recent Developments/Strategic Initiatives
- 8.4.8. F. Hoffmann-La Roche Ltd (Genentech, Inc.)
  - 8.4.8.1. Participant's Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Recent Developments/Strategic Initiatives
- 8.4.9. UCB S.A.
  - 8.4.9.1. Participant's Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Recent Developments/Strategic Initiatives
- 8.4.10. Salix Pharmaceuticals
  - 8.4.10.1. Participant's Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Recent Developments/Strategic Initiatives
- 8.4.11. Gilead Sciences Inc.
  - 8.4.11.1. Participant's Overview
  - 8.4.11.2. Financial Performance
  - 8.4.11.3. Product Benchmarking
  - 8.4.11.4. Recent Developments/Strategic Initiatives

Crohn's Disease Therapeutics Market Size, Share & Trends Analysis Report By Type, By Route of Administration (Injectable, Oral), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030